Medicover increases ownership in NIPD Genetics to 87.2%

Medicover AB committed to acquire shares from existing shareholders to increase its ownership in NIPD Genetics from 18.9% to 87.2%. The purchase price for the 68.3% stake is EUR 44.4 million, implying an enterprise value of EUR 65.0 million.

“NIPD's proprietary technology platform together with their experienced expert team and Medicover Genetics state-of-the art diagnostics will take us one step closer to become an international market leader in genetic diagnostics”inderes.dk

• 1 source
• inderes.dkMedicover: Increased ownership in NIPD Genetics - InderesDec 8, 2022

Summarized from public sources; check the original articles before acting on it.